Daiichi Sankyo Rolls Out Generics In Japan While Ranbaxy Products Still On Hold In U.S.
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Daiichi Sankyo has initiated operations for its Ranbaxy-supported generics subsidiary in Japan - Daiichi Sanyko Espha - a positive step for the company's established products plans as it awaits news on U.S. FDA action on Ranbaxy